HK Stock Market Move | REMEGEN(09995) rose more than 4%. The approval for the domestic market launch of Vedcizumab Monoclonal Antibody for first-line treatment of HER2-expressing urinary tract epithelial cancer was obtained.

REMEGEN (09995) rose more than 4%, as of the time of writing, it was up 4.43% to HK$110.7, with a turnover of HK$2.35 billion. In terms of news, on April 10th, REMEGEN announced that its self-developed antibody-drug conjugate (ADC) medication, Vedotinab, had been officially approved by the National Medical Products Administration for a new indication. It is used in combination with trastuzumab to treat locally advanced or metastatic urothelial carcinoma patients with HER2 expression, defined as HER2 immunohistochemistry results of 1+, 2+, or 3+. REMEGEN stated that this marks the successful expansion of Vedotinab's treatment range from second-line to first-line, bringing a new treatment option for Chinese patients with advanced urothelial carcinoma with HER2 expression, and becoming the world's first approved first-line treatment for advanced urothelial carcinoma with an HER2-ADC drug.